Juvenescence enhances AI drug discovery with Ro5 acquisition
The platform enables evaluation of drug targets based on therapeutic, biological and market potential.
Artificial Intelligence
Pharma’s AI prospects get nudged into the future with EU’s AI act
Next-generation targeting for evolving HCP engagement
Are regulators keeping pace with AI adoption in clinical trials?
Recursion axes drug programmes to streamline pipeline
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
3 reasons why biotechs preparing for launch need a compliant content foundation
